Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders

Bibliography

• Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006;114:217-38
   PubMed Web of Science ®Google Scholar
• Canafoglia L, Franceschetti S, Antozzi C, Epileptic phenotypes associated with mitochondrial disorders. Neurology 2001;56:1340-6
   PubMed Web of Science ®Google Scholar
• Lam CW, Lau CH, Williams JC, Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997;156:562-4
   PubMed Web of Science ®Google Scholar
• Finsterer J, Barton P. Regression of stroke-like lesions in MELAS-syndrome after seizure control. Epileptic Disord 2010;12:330-4
   PubMed Web of Science ®Google Scholar
• Corda D, Rosati G, Deiana GA, "Erratic" complex partial status epilepticus as a presenting feature of MELAS. Epilepsy Behav 2006;8:655-8
   PubMed Web of Science ®Google Scholar
• Battaglia A, Filippi T, South ST, Spectrum of epilepsy and electroencephalogram patterns in Wolf-Hirschhorn syndrome: experience with 87 patients. Dev Med Child Neurol 2009;51:373-80
   PubMed Web of Science ®Google Scholar
• Valente KD, Freitas A, Fiore LA, A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders. Brain Dev 2003;25:283-7
   PubMed Web of Science ®Google Scholar
• Costello DJ, Sims KB. Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA A3243G mutation. Neurology 2009;72:1279-80
   PubMed Web of Science ®Google Scholar
• Desguerre I, Pinton F, Nabbout R, Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics 2003;34:265-9
   PubMed Web of Science ®Google Scholar
• Letsas KP, Efremidis M, Pappas LK, Pathophysiology and management of syncope in Kearns-Sayre syndrome. Am Heart Hosp J 2006;4:301-2
   PubMedGoogle Scholar
• Ramaekers VT, Weis J, Sequeira JM, Mitochondrial complex I encephalomyopathy and cerebral 5-methyltetrahydrofolate deficiency. Neuropediatrics 2007;38:184-7
   PubMed Web of Science ®Google Scholar
• Kagitani-Shimono K, Imai K, Otani K, Epilepsy in Wolf-Hirschhorn syndrome (4p-). Epilepsia 2005;46:150-5
   PubMed Web of Science ®Google Scholar
• Urbanska EM, Blaszczak P, Saran T, Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur J Pharmacol 1998;359:55-8
   PubMed Web of Science ®Google Scholar
• Koga Y, Povalko N, Katayama K, Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev 2011; In press
   PubMed Web of Science ®Google Scholar
• Koga Y, Povalko N, Nishioka J, MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 2010;1201:104-10
   PubMed Web of Science ®Google Scholar
• Barnerias C, Saudubray JM, Touati G, Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol 2010;52:e1-9
   PubMed Web of Science ®Google Scholar
• Lee YM, Kang HC, Lee JS, Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008;49:685-90
   PubMed Web of Science ®Google Scholar
• Seo JH, Lee YM, Lee JS, A case of Ohtahara syndrome with mitochondrial respiratory chain complex I deficiency. Brain Dev 2010;32:253-7
   PubMed Web of Science ®Google Scholar
• Kang HC, Kim HD, Lee YM, Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr Neurol 2006;35:158-61
   PubMed Web of Science ®Google Scholar
• Kim do Y, Rho JM. The ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care 2008;11:113-20
   PubMed Web of Science ®Google Scholar
• Toribe Y, Tominaga K, Ogawa K, Usefulness of L-arginine infusion for status epilepticus in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. No To Hattatsu 2007;39:38-43
   PubMedGoogle Scholar
• Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008;82:219-22
   PubMed Web of Science ®Google Scholar
• Castro-Cago M, Gonzalez-Conde V, Fernandez-Seara MJ, Early mitochondrial encephalomyopathy due to complex IV deficiency consistent with Alpers-Huttenlocher syndrome: report of two cases. Rev Neurol 1999;29:912-17
   PubMed Web of Science ®Google Scholar
• Chabrol B, Mancini J, Chretien D, Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 1994;153:133-5
   PubMed Web of Science ®Google Scholar
• Krahenbuhl S, Brandner S, Kleinle S, Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000;20:346-8
   PubMedGoogle Scholar
• Stollberger C, Hoftberger R, Finsterer J. Lamotrigine-trigged obstructive hypertrophic cardiomyopathy, epilepsy and metabolic myopathy. Int J Cardiol 2011;149:e103-5
   Google Scholar
• Chiyonobu T, Noda R, Yoshida M, Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 2008;30:430-3
   PubMed Web of Science ®Google Scholar
• Allen RJ, DiMauro S, Coulter DL, Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983;13:679-82
   PubMed Web of Science ®Google Scholar
• Shchelochkov O, Wong LJ, Shaibani A, Atypical presentation of VLCAD deficiency associated with a novel ACADVL splicing mutation. Muscle Nerve 2009;39:374-82
   PubMed Web of Science ®Google Scholar
• Hsu YC, Yang FC, Perng CL, Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (melas) syndrome presenting as acute meningoencephalitis: a case report. J Emerg Med 2009; In press
   PubMedGoogle Scholar
• Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007;22:105-9
   PubMed Web of Science ®Google Scholar
• Rasmussen M, Sanengen T, Skullerud K, Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease. J Child Neurol 2000;15:473-7
   PubMed Web of Science ®Google Scholar
• Pronicka E, Weglewska-Jurkiewicz A, Pronicki M, Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit 2011;17:CR203-9
   Google Scholar
• Bicknese AR, May W, Hickey WF, Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 1992;32:767-75
   PubMed Web of Science ®Google Scholar
• Kayihan N, Nennesmo I, Ericzon BG, Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant 2000;4:211-14
   PubMedGoogle Scholar
• Saneto RP, Lee IC, Koenig MK, POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010;19:140-6
   PubMed Web of Science ®Google Scholar
• Schaller A, Hahn D, Jackson CB, Molecular and biochemical characterisation of a novel mutation in POLG associated with Alpers syndrome. BMC Neurol 2011;11:4
   PubMedGoogle Scholar
• Schwabe MJ, Dobyns WB, Burke B, Valproate-induced liver failure in one of two siblings with Alpers disease. Pediatr Neurol 1997;16:337-43
   PubMed Web of Science ®Google Scholar
• Simonati A, Filosto M, Savio C, Features of cell death in brain and liver, the target tissues of progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher disease). Acta Neuropathol 2003;106:57-65
   PubMed Web of Science ®Google Scholar
• Wolf NI, Rahman S, Schmitt B, Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009;50:1596-607
   PubMed Web of Science ®Google Scholar
• Uusimaa J, Hinttala R, Rantala H, Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 2008;49:1038-45
   PubMed Web of Science ®Google Scholar
• Hakonen AH, Isohanni P, Rantamaki M, Mitochondrial recessive ataxia syndrome (MIRAS) and valproate toxicity. Duodecim 2010;126:1552-9
   PubMedGoogle Scholar
• Mancuso M, Galli R, Pizzanelli C, Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006;243:97-9
   PubMed Web of Science ®Google Scholar
• Ponchaut S, van Hoof F, Veitch K. Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 1992;43:644-7
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Menchise V, Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315-20
   PubMed Web of Science ®Google Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(suppl 1):S35-9
   PubMed Web of Science ®Google Scholar
• Santos NA, Medina WS, Martins NM, Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. Toxicol In Vitro 2008;22:1143-52
   PubMed Web of Science ®Google Scholar
• Hroudova J, Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neurol Endocrinol Lett 2010;31:336-42
   PubMed Web of Science ®Google Scholar
• Araujo IM, Ambrosio AF, Leal EC, Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004;45:1498-505
   PubMed Web of Science ®Google Scholar
• Riva R, Albani F, Contin M, Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996;31:470-93
   PubMed Web of Science ®Google Scholar
• Goto M, Miyahara I, Hirotsu K, Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. J Biol Chem 2005;280:37246-56
   PubMed Web of Science ®Google Scholar
• Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr 2001;131:846S-50S
   Web of Science ®Google Scholar
• Santos NA, Medina WS, Martins NM, Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs. Toxicol In Vitro 2008;22:1820-4
   PubMed Web of Science ®Google Scholar
• Berger I, Segal I, Shmueli D, The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J Child Neurol 2010;25:541-5
   PubMed Web of Science ®Google Scholar
• Bachmann RF, Wang Y, Yuan P, Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009;12:805-22
   PubMed Web of Science ®Google Scholar
• Tomimoto H, Nakano S, Matsuda M. Report of a case of Kearns-Sayre syndrome associating with Isaacs-Mertens syndrome. No To Shinkei 1988;40:771-7
   PubMedGoogle Scholar
• Costa C, Tozzi A, Luchetti E, Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 2010;221:217-24
   PubMed Web of Science ®Google Scholar
• Costa C, Belcastro V, Tozzi A, Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 2008;28:8040-52
   PubMed Web of Science ®Google Scholar
• Lai JS, Zhao C, Warsh JJ, Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 2006;539:18-26
   PubMed Web of Science ®Google Scholar
• Rumbach L, Mutet C, Cremel G, Effects of sodium valproate on mitochondrial membranes: electron paramagnetic resonance and transmembrane protein movement studies. Mol Pharmacol 1986;30:270-3
   PubMed Web of Science ®Google Scholar
• Connop BP, Boegman RJ, Beninger RJ, Malonate-induced degeneration of basal forebrain cholinergic neurons: attenuation by lamotrigine, MK-801, and 7-nitroindazole. J Neurochem 1997;68:1191-9
   PubMed Web of Science ®Google Scholar
• Lagrue E, Chalon S, Bodard S, Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res 2007;62:14-19
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, Diaz-Corrales FJ, Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 2010;67:239-49
   PubMed Web of Science ®Google Scholar
• Kudin AP, Debska-Vielhaber G, Vielhaber S, The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004;45:1478-87
   PubMed Web of Science ®Google Scholar
• Monti B, Gatta V, Piretti F, Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 2010;17:130-41
   PubMed Web of Science ®Google Scholar
• Chen X, Wong JY, Wong P, Radany EH. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 2011;9:448-61
   PubMed Web of Science ®Google Scholar
• Ponchaut S, van Hoof F, Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 1992;43:2435-42
   PubMed Web of Science ®Google Scholar
• Gordon N. Alpers syndrome: progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol 2006;48:1001-3
   PubMed Web of Science ®Google Scholar
• Harden CL. Therapeutic safety monitoring: what to look for and when to look for it. Epilepsia 2000;41(suppl 8):S37-44
   Google Scholar
• Luis PB, Ruiter JP, Aires CC, Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim Biophys Acta 2007;1767:1126-33
   PubMed Web of Science ®Google Scholar
• Shoffner JM. Mitochondrial Neurogastrointestinal Encephalopathy Disease. 2005 Apr 22 [updated 2010 May 11]. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. University of Washington; Seattle, Seattle (WA): 1993. Available from: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=mngie
   Google Scholar
• Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26(suppl 2):43-53
   PubMed Web of Science ®Google Scholar
• Ponchaut S, Draye JP, Van Hoof F, Loss of hepatic cytochrome aa3 during chronic valproate treatment: dissociation of proton pumping and electron transport in Complex IV. Biochem Soc Trans 1991;19:253S
   Google Scholar
• Haas R, Stumpf DA, Parks JK, Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981;31:1473-6
   PubMed Web of Science ®Google Scholar
• Eyer F, Felgenhauer N, Gempel K, Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 2005;25:376-80
   PubMed Web of Science ®Google Scholar
• Miyatake M, Kuno T, Kita A, Valproic acid affects membrane trafficking and cell-wall integrity in fission yeast. Genetics 2007;175:1695-705
   PubMed Web of Science ®Google Scholar
• Dzimiri N. Effects of procainamide, tocainide and phenytoin on guinea pig cardiac mitochondrial ATPase activity. Res Commun Chem Pathol Pharmacol 1993;80:121-4
   PubMedGoogle Scholar
• Gilbert JC, Wyllie MG. Effects of anticonvulsant and convulsant drugs on the ATPase activities of synaptosomes and their components. Br J Pharmacol 1976;56:49-57
   PubMed Web of Science ®Google Scholar
• Nabe K, Fujimoto S, Shimodahira M, Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology 2006;147:2717-27
   PubMed Web of Science ®Google Scholar
• Riikonen R. The latest on infantile spasms. Curr Opin Neurol 2005;18:91-5
   PubMed Web of Science ®Google Scholar
• Kim YJ, Ko HH, Han ES, Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res Bull 2007;71:633-40
   PubMed Web of Science ®Google Scholar
• Ueda Y, Doi T, Takaki M, Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res 2009;1266:1-7
   PubMed Web of Science ®Google Scholar
• Vargas F, Vargas P, Aoki K, In vivo and in vitro effects of phenytoin (PHT) on ATPases and [14C]-PHT binding in synaptosomes and mitochondria from rat cerebral cortex. Epilepsia 1994;35:882-8
   PubMed Web of Science ®Google Scholar